NEW YORK, Sept. 5 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX) and H. Lundbeck A/S of Denmark said today that the U.S. Court
of Appeals for the Federal Circuit has affirmed a July 13, 2006 decision by
the U.S. District Court for the District of Delaware which determined that
the U.S. patent covering escitalopram, the active ingredient in Lexapro(R),
is valid and upheld the injunction preventing Ivax/Teva's proposed generic
product launch, thereby confirming Forest's and Lundbeck's patent rights
for Lexapro(R), which expire in March 2012.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
The patent at issue in the U.S. lawsuit is Lexapro's patent (U.S.
Patent No. Re 34,712), which is set to expire in March 2012 and covers
substantially pure escitalopram.
About Forest Laboratories and Its Products
Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical company
dedicated to identifying, developing and delivering products that make a
positive difference in peoples' lives. Forest Laboratories' growing product
line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for
adults for the initial and maintenance treatment of major depressive
disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an
N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate to severe Alzheimer's disease; Benicar(R)*
(olmesartan medoxomil), an angiotensin receptor blocker, and Benicar*
HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor
blocker and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated in
combination with psychosocial support for the maintenance of abstinence
from alcohol in patients with alcohol dependence who are abstinent at
treatment initiation.
*Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral
is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany.
Except for the historical information contained herein, this release
contains "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
the Forest Laboratories' SEC reports, including the Company's Annual Report
on Form 10-K for the fiscal year ended March 31, 2007 and quarterly report
on form 10-Q for the period ended June 30, 2007.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Charles E. Triano, Vice President-Investor
Relations of Forest Laboratories, Inc., +1-212-224-6714,
charles.triano@frx.com
|
